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1004.1-9 Prevention of Renal Function Woreening After 
Percutaneous Coronary Interventions by Hemofiltration 
in Patients at High Risk for Contrast Nephropathy 
Giancarlo, Gianfranco Laud, Emilio Assanelli. Marco Grazi, Jeness 
Campodonico. lvana Marana, Daniela Trabattoni, Antonio L. Bartorelli. Centro 
Car&logic0 Monzino, IRCCS, institute of Cardiology, University of Milan, Milan, /&I/F 
Background. Radiocontrast exposure and hemodynamic instability during percutaneous 
coronary interventions (PCI) can cause renal dysfunction requiring hemodialysis (HD). 
especially in patients with pre-existent renal failure (RF). RF requiring HD is associated 
with poor outcomes, including a 40% in-hospital mortality. Therefore, preventive strate- 
gies to avoid acute RF are of considerable interest. Continuous venovenous hemofiltra- 
tion (CVVH) allows: 1) high volume, controlled hydration before and after exposure to 
contrast 2) its removal from the circulation 3) vascular stability. We investigated the role 
of CVVH, as compared with isotonic hydration, in preventing contrast nephropathy in 
high-risk patients. 
Methods. 54 pts with RF (creatinine >2 mg/dl) underwent either CVVH (n=34; two-lumen 
cannula in a femoral vein; fluid replacement:1000 mllhr, no weight loss), or hydration with 
saline (n=20; 1 ml/kg/h) for the 24hrs before and after PCI. 
Results. 
At discharge, creatinine increased (>0.5 mgldf) in 6% pts of CVVH and in 60% of saline 
group (p<O.OOl). Temporary HD was required in 39% and permanent HD in 10% of the 
saline group and in 0% of CVVH group. In-hospital mortality was 3% in CVVH and 22% 
in saline group. (p-zO.01). Renal function data are shown in the table (‘=pcO.Ol vs. 
CVVH; #=p<O.Ol vs. baseline). 
Conclusions. In patients with CRF undergoing PCI, periprocedural CVVH is effective to 
prevent renal function deterioration due to contrast nephrotoxicity and lo improve in-hos- 
pital prognosis. 
Baseline Before End of CVVHI Hospital 
PCI saline Discharge 
Diuresis(ml/24h) CVV 1517+38 1422*367 1905+1072 1630*370 
H 1 
saline 1490+43 1532i460 720*1100’# 805+98o^#l 
0 
BUN (mg/dl) CVV 132+44 88*29# 75&13# 94i51# 
H 
saline 138*56 122i46’ 17&110’# 165+122’# 
Creatinine (mg/ CVV 2.9iO.9 2.1+0.6# 2.1*0.5# 2.7+0.9 
dl) H 
saline 2.8i0.9 2.7*1’ 3.5i1.2’# 3.1*1’# 
1004.1-10 The Role of Mucomyst Administration Prior to 
Percutaneous Interventions on Renal Function in 
Patients With Chronic Renal Failure 
b&~.LAdamian. lssam Moussa, Roxana Mehran, George Dangas, Michael Farkhou. 
Yuliya Adamyan. Mohamed Mohamed, Andrei Negoita, Arlene Reyes. Monica 
Losquadro, Michael Collins, Edward M. Kreps. Jeffrey W. Moses, Gregg W. Stone, 
Martin 8. Leon, Lenox Hi// Head and Vascular Institute, New York. New York, 
Cardiovascular Research Foundation, New York, New York. 
Background: Recent studies have suggested that nephrotoxicity of contrast agents in 
patients with chronic renal insufficiency (CRI) undergoing CT scanning could be attenu- 
ated by administration of the antioxidant Aceiylcysteine (Mucomyst). However, it is 
unknown whether Mucomyst (M) can be as effective during percutaneous coronary inter- 
ventions (PCI) in patients with CAL 
Methods: Between November 2001 and June 2001 we evaluated 57 consecutive 
patients with baseline serum creatinine >1.5 and e3.4 mg/dl (not on hemodialysis) who 
undenvent PCI using iso-osmolar non-ionic contrast agent (lodixanol). Out of this group, 
35 patients received Mucomyst (600 mg bid) with IV hydration (M group), and 22 pts 
received only IV hydration (Non-M group). Peak post-procedure serum creatinine (SC) 
levels during the following 48 hours were obtained. Contrast-induced nephropathy (CIN) 
was defined as 25% increase in SC levels compared to baseline SC value. 
Results: There were no differences between the M and No-M groups in age (71 + 10 vs. 
72 f 10. p=O.62). diabetes mellitus (57% vs. 70%. p=O.55) or other risk factors. The No- 
M group included more females (50% vs. 14% ~=0.006). 
M (n=35) No-M (n=22) P-value 
Baseline Creatinine (mg/dl) 1.89 + 0.44 1.96 ? 0.5 0.62 
Peak Creatinine (mg/dl) at 48 hrs 1.88 r 1 .O 2.48 + 1.3 0.05 
CIN (%) 2.9 36.4 0.002 
In-Hospital Dialysis (%) 2.9 13.7 0.29 
ACCIS2002 (Angiography & Interventional Cardiology) 1A 
Conclusion: f&corny& administration prior to PCI in CRI patients has protective effect 
on renal function. Randomized prospective trials are required to determine the validity of 
these findings. 
1004.1-11 Prevention of Contrast-Induced Renal Dysfunction With 
Acetylcysteine in Patients Undergoing Coronary 
Angiography 
sN. George Tadros, Akin A. 0. Akinwande, Brenda Campbell, James C. 
Blankenship, Elias A. Iliadis, Geisinger Medical Center, DanviNe, Pennsylvania 
Background: Acetylcysteine in patients undergoing CT scan imaging with intravenous 
contrast reduces the incidence of acute renal dysfunction. We examined the effect of 
acetylcysteine in patients undergoing coronary angiography. Methods: Fifty five consec- 
utive patients receiving 3 doses of acetylcysteine prior to cardiac catheterization were 
compared to 55 historical controls. All patients in both groups had baseline serum creati- 
nine L l.Pmg/dl and received intravenous hydration before and after the procedure. 
Serum cteatinine levels a1 baseline and 48 hours after procedure were compared. 
Results: Univariate analysis of clinical variables revealed no significant difference 
between the groups except for a higher mean baseline creatinine in the treatment group 
(2(+/-0.7) vs 1.8(+/-0.4) mg/dl, p=O.O4). There was no difference in the amount or type of 
contrast used. The mean change in creatinine after 48 hours was - 0.4(+/-0.3) vs + O.l(+/ 
-0.3) mg/dl for treatment and control groups (pcO.001). In patients with baseline Cr > 2 
mg/dl, the benefit was larger (-0.4(+/-0.4) vs + 0.5(+/-0.3) mg/dl, peO.OOl)(Table). Multi- 
variate analysis confirmed pre-treatment with acetylcysteine as an independent predictor 
of renal protection (p<O.OQl). Conclusions: Prophylactic use of acetylcysteine pre- 
vented reduction of renal function after coronary angiography The benefit was greater in 
patients with baseline serum creatinine > 2 mg/dl. 
Baseline Craatinlne 2 1.2 Acelylcysteine group 
07 = 551 
Control group p-value 
In = 55) 
Baseline creatinine, mean (SD) 2.0 (0.7) 1.8 (0.4) 0.041 
Change after 48 hrs, mean (SD) -0.4 (0.3) 0.1 (0.3) < 0.001 
Baseline Creatlnlne 2 2.0 Acetylcysteine group Control group p-value 
(n= 15) (n = 9) 
Baseline creatinine, mean (SD) 2.6 (1.1) 2.5 (0.7) 0.741 
Chanae after 48 hrs. mean (SD) -0.4 10.4) 0.5 (0.3~ eo.001 
1004.1-12 Clinical Outcomes in Patients With Chronic Renal 
Dysfunction Following Percutaneous Coronary 
Intervention: A Report From the New York State 
Angioplasty Registry 
Robert M. Minut&, Eric T. Chou, Mun K. Hong, S. Chiu Wang, New York Presbyterian 
Hospital - Come/{ Medical Center. New York, New York. 
Background: Patients with chronic renal failure (CRF) often have comorbidities Mat 
place them at higher risk for adverse outcomes following percutaneous coronary inter- 
ventions. Whether renal dysfunction itself is an independent predictor for post-procedural 
major adverse cardiac events (MACE) is less evident. 
Methods: Using the 1995 New York State PTCA Database, we compared baseline char- 
acteristics and in-hospital events between patients with chronic renal failure (creatinine 
>2.5 or requiring hemodialysis) and those without significant renal insufficiency. We then 
sought to determine whether renal dysfunction was a significant independent predictor of 
MACE (death, emergent CABG, QWMI). 
Results: (see table) Patients with renal disease had higher rates of hypeltension (HTN). 
diabetes, prior myocardial infarctions (MI) and peripheral vascular disease (PVD). HOW- 
ever, when using multivariate logistic regression analysis, renal dysfunction remained a 
strong independent predictor (OR=2.5. p=O.OOl, 95% C.I. 1.47-4.35) of MACE. 
Conclusion: Chronic renal disease is a significant independent risk factor for MACE fol- 
lowing percutaneous coronary intervention. There is a several-fold increase in post-pro- 
cedural moltality in patients with renal failure. 
No CRF 
fN=22.218) 
CRF 
IN=3701 
P value 
Patient Factors: 
Age (years)/Male(%) 
HTN(%)/Diabetes(%) 
Prior MI(%)/CABG(%) 
Smoking(%)/PVD(%) 
In Hospital Events: 
MACE(%) 
DeathlClWMIICABG(%) 
CVA (%) 
62/69 65/65 <0.01/0.08 
60/l 9 84145 <O.OOl 
8/13 13/22 <O.OOl 
2619 1 O/32 <O.OOl 
1.1 4.9 co.oo1 
0.6/ 0.3/l .4 4.3/0.0/l .9 <0.001/0.63/0.42 
2.5 6.8 <O.OOl 
Contrast Volume (cc) 273f113 303r152 0.47 
